Exact Mass: 474.2042
Exact Mass Matches: 474.2042
Found 160 metabolites which its exact mass value is equals to given mass value 474.2042
,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
Sildenafil
Sildenafil is a drug used to treat male erectile dysfunction (impotence) and pulmonary arterial hypertension (PAH), developed by the pharmaceutical company Pfizer. It was initially studied for use in hypertension (high blood pressure) and angina pectoris (a form of ischaemic cardiovascular disease). Phase I clinical trials under the direction of Ian Osterloh suggested that the drug had little effect on angina, but that it could induce marked penile erections; Sildenafil is a potent and selective inhibitor of cGMP specific phosphodiesterase type 5 (PDE5) which is responsible for degradation of cGMP in the corpus cavernosum. The molecular structure of sildenafil is similar to that of cGMP and acts as a competitive binding agent of PDE5 in the corpus cavernosum, resulting in more cGMP and better erections. Without sexual stimulation, and therefore lack of activation of the NO/cGMP system, sildenafil should not cause an erection. Other drugs that operate by the same mechanism include tadalafil (Cialis) and vardenafil (Levitra); Sildenafil citrate, sold under the names Viagra, Revatio and generically under various other names, is a drug used to treat male erectile dysfunction (impotence) and pulmonary arterial hypertension (PAH), developed by the pharmaceutical company Pfizer. Viagra pills are blue and diamond-shaped with the words Pfizer on one side, and VGR xx (where xx stands for 25, 50 or 100, the dose of that pill in milligrams) on the other. Its primary competitors on the market are tadalafil (Cialis), and vardenafil (Levitra). Sildenafil is a drug used to treat male erectile dysfunction (impotence) and pulmonary arterial hypertension (PAH), developed by the pharmaceutical company Pfizer. G - Genito urinary system and sex hormones > G04 - Urologicals > G04B - Urologicals > G04BE - Drugs used in erectile dysfunction D004791 - Enzyme Inhibitors > D010726 - Phosphodiesterase Inhibitors > D058986 - Phosphodiesterase 5 Inhibitors C471 - Enzyme Inhibitor > C744 - Phosphodiesterase Inhibitor > C2127 - cGMP Phosphodiesterase Inhibitor COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials C78274 - Agent Affecting Cardiovascular System > C29707 - Vasodilating Agent D000089162 - Genitourinary Agents > D064804 - Urological Agents D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
2-((2'-(5-Ethyl-3,4-diphenyl-1H-pyrazol-1-yl)-[1,1'-biphenyl]-3-yl)oxy)acetic acid
BMS-309403 is a potent, orally active and selective adipocyte fatty acid binding protein (also known as FABP4, aP2) inhibitor with Kis of <2, 250, and 350 nM for FABP4, FABP3, and FABP5, respectively. BMS-309403 interacts with the fatty-acid-binding pocket within the interior of the protein and competitively inhibits the binding of endogenous fatty acids. BMS-309403 improves endothelial function in apolipoprotein E-deficient mice and in cultured human endothelial cells[1][2][3].
Ibrutinib metabolite M37
Mitopodozidum
N-(2-Benzyl-3-((2-amino-4-methylpentyl)dithio)-1-oxopropyl)glycine benzyl ester
NSC 72274; Podophyllic acid ethylhydrazide; Podophyllinic acid 2-ethylhydrazide
Carvacrol 2-O-??-glucopyranosyl-(1鈥樏傗垎2)-??-glucopyranoside|carvacrol 20O-beta-glucopyranosyl-(1-2)-beta-glycopyranoside
4-hydroxy-2-isopropyl-5-methylphenyl O-alpha-L-rhamnopyranosyl-(1->2)-beta-D-glucopyranoside
Asn Val Gln Asp
sildenafil
G - Genito urinary system and sex hormones > G04 - Urologicals > G04B - Urologicals > G04BE - Drugs used in erectile dysfunction D004791 - Enzyme Inhibitors > D010726 - Phosphodiesterase Inhibitors > D058986 - Phosphodiesterase 5 Inhibitors C471 - Enzyme Inhibitor > C744 - Phosphodiesterase Inhibitor > C2127 - cGMP Phosphodiesterase Inhibitor COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials C78274 - Agent Affecting Cardiovascular System > C29707 - Vasodilating Agent D000089162 - Genitourinary Agents > D064804 - Urological Agents D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
Ala Glu Gln Gln
Ala Gln Glu Gln
Ala Gln Gln Glu
Asp Phe Pro Pro
Asp Ile Asn Asn
Asp Leu Asn Asn
Asp Asn Ile Asn
Asp Asn Leu Asn
Asp Asn Asn Ile
Asp Asn Asn Leu
Asp Asn Gln Val
Asp Asn Val Gln
Asp Pro Phe Pro
Asp Pro Pro Phe
Asp Gln Asn Val
Asp Gln Val Asn
Asp Val Asn Gln
Asp Val Gln Asn
Glu Ala Gln Gln
Glu Glu Pro Thr
Glu Glu Thr Pro
Glu Asn Asn Val
Glu Asn Val Asn
Glu Pro Glu Thr
Glu Pro Thr Glu
Glu Gln Ala Gln
Glu Gln Gln Ala
Glu Thr Glu Pro
Glu Thr Pro Glu
Glu Val Asn Asn
Phe Asp Pro Pro
Phe Pro Asp Pro
Phe Pro Pro Asp
Ile Asp Asn Asn
Ile Asn Asp Asn
Ile Asn Asn Asp
Leu Asp Asn Asn
Leu Asn Asp Asn
Leu Asn Asn Asp
Met Met Pro Pro
Met Pro Met Pro
Met Pro Pro Met
Asn Asp Ile Asn
Asn Asp Leu Asn
Asn Asp Asn Ile
Asn Asp Asn Leu
Asn Asp Gln Val
Asn Asp Val Gln
Asn Glu Asn Val
Asn Glu Val Asn
Asn Ile Asp Asn
Asn Ile Asn Asp
Asn Leu Asp Asn
Asn Leu Asn Asp
Asn Asn Asp Ile
Asn Asn Asp Leu
Asn Asn Glu Val
Asn Asn Ile Asp
Asn Asn Leu Asp
Asn Asn Val Glu
Asn Gln Asp Val
Asn Gln Val Asp
Asn Val Asp Gln
Asn Val Glu Asn
Asn Val Asn Glu
Pro Asp Phe Pro
Pro Asp Pro Phe
Pro Glu Glu Thr
Pro Glu Thr Glu
Pro Phe Asp Pro
Pro Phe Pro Asp
Pro Met Met Pro
Pro Met Pro Met
Pro Pro Asp Phe
Pro Pro Phe Asp
Pro Pro Met Met
Pro Thr Glu Glu
Gln Ala Glu Gln
Gln Ala Gln Glu
Gln Asp Asn Val
Gln Asp Val Asn
Gln Glu Ala Gln
Gln Glu Gln Ala
Gln Asn Asp Val
Gln Asn Val Asp
Gln Gln Ala Glu
Gln Gln Glu Ala
Gln Val Asp Asn
Gln Val Asn Asp
Thr Glu Glu Pro
Thr Glu Pro Glu
Thr Pro Glu Glu
Val Asp Asn Gln
Val Asp Gln Asn
Val Glu Asn Asn
Val Asn Asp Gln
Val Asn Glu Asn
Val Asn Asn Glu
Val Asn Gln Asp
Val Gln Asp Asn
Val Gln Asn Asp
ETHYL 4-(2,4-BIS(BENZYLOXY)-5-ISOPROPYLPHENYL)-2-HYDROXY-4-OXOBUT-2-ENOATE
butyl prop-2-enoate,2-methylprop-2-enoic acid,2-methyl-2-(prop-2-enoylamino)propane-1-sulfonic acid,prop-2-enenitrile
N-[2-(4-{[4-(Cyclobutylamino)-5-(trifluoromethyl)-2-pyrimidinyl]amino}-11-azatricyclo[6.2.1.02,7]undeca-2,4,6-trien-11-yl)-2-oxoethyl]acetamide
MITOPODOZIDE
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C274 - Antineoplastic Agent > C1931 - Antineoplastic Plant Product > C1331 - Epipodophyllotoxin Compound C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C1748 - Topoisomerase Inhibitor D000970 - Antineoplastic Agents C1907 - Drug, Natural Product
pf-03814735
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C61074 - Serine/Threonine Kinase Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor